Allotransplantation is the process of transferring organ(s), tissue(s) or cell(s) from a healthy donor to a recipient. The two main applications of allotransplantation are solid organ transplantation and allogeneic hematopoietic stem cell transplantation. For several reasons, including the need to use immunosuppressive drugs after transplantation, recipients of allografts carry a high risk of infectious complications. Central nervous system infections are dreadful complications of transplantation, which can be divided into brain abscesses, meningitis, and encephalitis. In particular, brain abscesses pose major diagnostic and therapeutic challenges to transplant physicians, and are frequently fatal in transplant recipients. As compared with immunocompetent patients, transplant recipients and other immunocompromised patients have an increased risk of brain abscesses due to opportunistic pathogens, including fungi, parasites, bacteria, and mycobacteria. Determining the epidemiology of brain abscesses is critical to guide transplant teams regarding the diagnosis and management of brain abscesses in transplant recipients. Because the incidence of brain abscesses is low after transplantation, transplant teams often have limited clinical experience in the management of these infections. Similarly, most publications focusing on post-transplant brain abscesses are either case reports, small case series, or review articles. We therefore aim to conduct a multicentre retrospective study on the epidemiology, the characteristics, and the outcome of brain abscesses in transplant recipients in the era of new diagnostic tools and progress in prophylaxis.
Study Type
OBSERVATIONAL
Enrollment
200
Data collection
Description of the current epidemiology of brain abscesses in transplant recipients
Clinical and microbiological characteristics
Time frame: 1 year after brain abscess diagnosis
Comparison of the clinical and microbiological characteristics of brain abscesses between solid organ transplant recipients and allogeneic hematopoietic stem cell transplant recipients
Time frame: 1 year after brain abscess diagnosis
Compare the clinical and microbiological characteristics of brain abscesses occurring early after transplantation (<M6) with those of brain abscesses occurring later after transplant (> M6)
Time frame: 1 year after brain abscess diagnosis
Identification of clinical predictors associated with fungal brain abscesses versus brain abscesses due to non-fungal organisms
Time frame: 1 year after brain abscess diagnosis
Description of the current management of post-transplant brain abscesses in transplant recipients
in terms of antimicrobial therapy, immunomodulation, and neurosurgical management
Time frame: 1 year after brain abscess diagnosis
Assessment of the outcome of transplant recipients with brain abscesses
i.e. one-year all cause mortality
Time frame: 1 year after brain abscess diagnosis
Identification of factors associated with patient survival in transplant recipients with brain abscesses
Time frame: 1 year after brain abscess diagnosis
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.